Webinar On FDA Guidance: Design Considerations for Pivotal Clinical Investigations for Medical Devices

MessageThis Webinar is over
Date Apr 14, 2014
Time 13:00
Cost $249.00
Online
This webinar introduces FDA’s guidance “Design Considerations for Pivotal Clinical Investigations in Medical Devices” that was published in late 2013. It discusses the regulatory considerations for clinical study design, and delves into the issues of bias and variance that may impact the quality of the data obtained in the study, as well as the interpretation of the data.

Following that, it discusses way that are available to a medical device sponsor, for eliminating bias and variance, both in terms of the study design and the requirements for the personnel that will design and run the studies. Finally, it touches on the study protocol and statistical plan and discusses ways to use those to ensure the success of the study.

In November 2013 the FDA issued the Guidance “Design Considerations for Pivotal Clinical Investigations for Medical Devices” to provide guidance to Industry, Clinical Investigators and Institutional Review Boards, on the study design principles relevant to the development of medical device clinical studies. Even though this guidance is focused on is providing recommendations to sponsors on how to design clinical investigations to support a PMA, sponsors who conduct clinical studies to support pre-market notification (510(k)) and de novo submissions may also rely on the principles in this guidance document.
Each year, insufficient evidence of the safety and effectiveness of a medical device caused from incorrect study design, results in the delay or rejection of either the medical device application or studies conducted towards that application. This is very expensive for the medical device sponsor who has to do additional work or redo existing work. It is also very expensive for the FDA (or other regulatory authorities) who spend the time to review results from incorrectly designed studies.

To mitigate these issues and standardize the way industry design clinical studies, the FDA published the guidance “Design Considerations for Pivotal Clinical Investigations in Medical Devices” in late 2013. The FDA’s goal in publishing this guidance is to help device manufacturers select the appropriate trial design to:
    Better support and improves the quality of safety & effectiveness data submitted to the agency
    Lead to timelier FDA approval
    Speed patients’ access to new devices

Areas Covered in the Session :

    The Guidance
    General Principles
    Some Principles for the Choice of Clinical Study Design
    Clinical Outcome Studies
    Diagnostic Clinical Performance Studies
    Sustaining the Quality of Clinical Studies
    Summary
    Q&A

Who Will Benefit:

    Clinical Trial Physician / Doctor
    Clinical Investigators
    Regulatory Affairs Management Team
    Quality Assurance Manegers & Directors
    Clinical Research & Management Team
    Data Management Team
    Data Monitoring Manegers & Directors
    Institutional Review Board
    Biostatisticians

Price tags:
Single Live : For One Participant
$ 249
Corporate Live : For Max. 10 Participants                                        
$ 899
Recording
Single REC : For One Participant - Unlimited Access for 6 Months
$ 299

Speaker Profile
Angela Bazigos is the CEO of Touchstone Technologies Silicon Valley, Inc. “Your Passport to Compliance”. She has 30 years of experience in the Life sciences industry spanning Project Management, Quality Assurance and Regulatory Affairs and has a patent aimed at speeding up Software Compliance. 

For booking slots and more information 
Contact Us:
Compliance Trainings
5939 Candlebrook Ct,
Mississauga, ON L5V 2V6,
Canada
Customer Support :
#416-915-4458
Email :
support@compliancetrainings.com

 


comments powered by Disqus
Create your own event
Turn your passion into a business.
Join our mailing list